UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 September
2025, London UK
GSK to invest $30 billion in R&D and Manufacturing in the
United States over next 5 years
●
Includes
new $1.2 billion investment announced today in manufacturing
facilities, AI and advanced digital technologies, creating hundreds
of highly skilled U.S. jobs
●
New
facilities will bridge R&D and manufacturing across both the
U.S. and U.K., strengthening the two countries' leadership in life
sciences
GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion
across the United States in research and development and supply
chain infrastructure over the next five years.
This includes a new $1.2 billion investment in advanced
manufacturing facilities and AI and advanced digital technologies,
to deliver new, next-generation biopharma factories and
laboratories in the United States. These investments build on GSK's
strong innovation and manufacturing footprint and capabilities in
the United States today, developing and making products in the
United States for the United States.
The $1.2 billion investment includes:
●
Construction
of an additional new biologics flex factory at Upper Merion,
Pennsylvania to deliver potential best-in-class new medicines for
respiratory disease (COPD, asthma) and cancer (haematological,
gynaecological, lung and other solid tumours). Construction is
planned to commence in 2026
●
New AI
and advanced digital technology capabilities across GSK's existing
5 manufacturing sites in 4 States (Pennsylvania, North Carolina,
Maryland, and Montana)
●
New drug
substance manufacturing capabilities
●
New
and enhanced device and auto-injector capabilities and
assembly
Commenting on the State Visit and today's
announcement, GSK CEO Emma Walmsley
said: "Alongside the many
longstanding and vital shared interests that connect the U.K. and
the United States, is advancing life sciences to get ahead of
disease. This week's State Visit brings together two countries that
have led the world in science and healthcare innovation. We
are proud to be part of both. Here in the U.K., we continue to
invest in a significant manufacturing base and more than £1.5
billion in R&D every year. Today, we are committing to invest
at least $30 billion in the United States over the next 5 years,
further bolstering the already strong R&D and supply chain we
have in the country. $1.2 billion of today's announcement includes
construction of an additional next-gen biologics "flex" factory,
powered by AI, advanced technologies and expert talent to produce
transformational new respiratory and cancer medicines for American
patients."
The $30 billion investment in the U.S. includes capital investments
across GSK's U.S. supply chain, as well as increased investment in
R&D drug discovery and development and clinical trial activity,
with the U.S. expected to rank first globally for the number of
studies, sites and clinical trials participants conducted by GSK
over the next five years.
Today's announcement means GSK has committed new investments of
approximately $2 billion in U.S. manufacturing over the last 12
months. In October 2024, construction began of a new $800 million
facility at GSK's Marietta, Pennsylvania site, doubling the size
and capacity of the site. These new manufacturing investments will
create hundreds of highly skilled jobs (in addition to construction
jobs), building upon GSK's approximately 15,000 strong U.S.
workforce.
Last year, GSK's global supply chain network delivered 1.7 billion
packs of medicines and over 400 million vaccine doses to help
towards our goal of positively impacting the health of 2.5 billion
people by the end of 2030.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: September
17, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|